We serve Chemical Name:N-(2,5-Dimethoxyphenyl)-2-hydroxydibenzofuran-3-carboxamide CAS:132-62-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:N-(2,5-Dimethoxyphenyl)-2-hydroxydibenzofuran-3-carboxamide
CAS.NO:132-62-7
Synonyms:2-hydroxy-dibenzofuran-3-carboxylic acid-(2,5-dimethoxy-anilide);Naphthol AS-DB;2-Hydroxy-dibenzofuran-3-carbonsaeure-(2,5-dimethoxy-anilid);Naphtanilide BT;2-hydroxy-2′,5′-dimethoxydibenzofuran-3-carboxanilide;Naphthanil DB;C.I. Azoic Coupling Component 16;3-Dibenzofurancarboxamide,N-(2,5-dimethoxyphenyl)-2-hydroxy;EINECS 205-069-2;Naphthol AS-BT
Molecular Formula:C21H17NO5
Molecular Weight:363.36300
HS Code:2932999099
Physical and Chemical Properties:
Melting point:N/A
Boiling point:503.9ºC at 760mmHg
Density:1.367g/cm3
Index of Refraction:1.711
PSA:80.93000
Exact Mass:363.11100
LogP:4.63410
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2-hydroxy-dibenzofuran-3-carboxylic acid-(2,5-dimethoxy-anilide) chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Naphthol AS-BT physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,C.I. Azoic Coupling Component 16 Use and application,2-hydroxy-2′,5′-dimethoxydibenzofuran-3-carboxanilide technical grade,usp/ep/jp grade.
Related News: In 2018, the Bengaluru-based Natural Capsules set up an R&D centre in at Attibele, Bengaluru. In 2020, when PLI scheme was announced it applied for the same. [(2R,3S,5R)-5-(2-amino-6-oxo-3H-purin-9-yl)-3-hydroxy-oxolan-2-yl]methoxyphosphonic acid manufacturers Professor Xiangdong Cheng, secretary of party committee of Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) and Chief of Zhejiang Province Upper Gastrointestinal Tumor Diagnosis and Treatment Technology Research Center, stated: The progress of immunotherapy in certain types of colorectal cancer and gastric cancer has not been satisfactory compared with the progress of anti-PD-1 monoclonal antibodies in melanoma, lung cancer and esophageal cancer, and this needs further exploration.
TIGIT is highly expressed in gastric cancer. And pre-clinical experiments have proved that synergistically targeting PD-1 and TIGIT could significantly repress gastric tumor growth. We look forward to the clinical results of IBI321, particularly in GI tumors.
Dr. Hui Zhou, Senior Vice President of Clinical Development of Innovent, stated: “By specifically targeting both PD-1 and TIGIT, this type of bispecific antibody is designed to provide synergistic effects by blocking both the PD-1/PD-L1 and TIGIT/CD155 pathways – with the goal of improving the anti-cancer efficacy.
Currently, there is no bispecific antibody that has same target as IBI321 in clinical-stage development worldwide. Preclinical studies of IBI321 have demonstrated that the combination of these two monoclonal antibodies further enhanced the immune activation with improved convenience of administration.
Therefore, the development of an anti-PD-1/TIGIT bispecific antibody has the potential to provide patients with more effective and convenient treatment. We look forward to hope that IBI321 will benefit more patients. 1-Butanone,1-[5-[1-[3,4-bis(difluoromethoxy)phenyl]-2-(4-pyridinyl)ethyl]-2-pyridinyl]-3-methyl- suppliers After a four-year battle over a cancer drug patent, Novartis has been ordered by a California judge to pay a Daiichi Sankyo subsidiary $177.8 million. 2-(4-chloro-phenyl)-5,6,7,8,9,10-hexahydro-2H-4a,8;6,10-dimethano-cycloocta[c]pyridazin-3-one vendor & factory.
TIGIT is highly expressed in gastric cancer. And pre-clinical experiments have proved that synergistically targeting PD-1 and TIGIT could significantly repress gastric tumor growth. We look forward to the clinical results of IBI321, particularly in GI tumors.
Dr. Hui Zhou, Senior Vice President of Clinical Development of Innovent, stated: “By specifically targeting both PD-1 and TIGIT, this type of bispecific antibody is designed to provide synergistic effects by blocking both the PD-1/PD-L1 and TIGIT/CD155 pathways – with the goal of improving the anti-cancer efficacy.
Currently, there is no bispecific antibody that has same target as IBI321 in clinical-stage development worldwide. Preclinical studies of IBI321 have demonstrated that the combination of these two monoclonal antibodies further enhanced the immune activation with improved convenience of administration.
Therefore, the development of an anti-PD-1/TIGIT bispecific antibody has the potential to provide patients with more effective and convenient treatment. We look forward to hope that IBI321 will benefit more patients. 1-Butanone,1-[5-[1-[3,4-bis(difluoromethoxy)phenyl]-2-(4-pyridinyl)ethyl]-2-pyridinyl]-3-methyl- suppliers After a four-year battle over a cancer drug patent, Novartis has been ordered by a California judge to pay a Daiichi Sankyo subsidiary $177.8 million. 2-(4-chloro-phenyl)-5,6,7,8,9,10-hexahydro-2H-4a,8;6,10-dimethano-cycloocta[c]pyridazin-3-one vendor & factory.
